Biotech company Primaa has raised €7 million to expand its AI cancer diagnostics software. The funding round was backed by MH Innov’, Elaia, and SWEN Capital Partners.
Primaa builds artificial intelligence tools to help pathologists analyze tissue samples. These tools automate the detection and quantification of key cancer biomarkers. This technology improves diagnostic reliability and reduces processing times. Its Cleo Breast product is certified in Europe. It assists with the automatic detection of breast cancer indicators. A second tool, Cleo Skin, is designed to diagnose several types of skin cancer from histological slides.
Primaa is also developing new solutions for cervical and prostate cancers.
The new capital will strengthen its sales organization for faster European deployment. It will also support the company's expansion into the United States, which includes planned FDA certification activities.